**MINUTES**

**CPIC CONFERENCE CALL**

DATE: May 6, 2021

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| CPIC guidelines in progress | CPIC guidelines in progress: * *CYP2C19*/clopidogrel update – drafting guideline
* *SLCO1B1*/simvastatin update – drafting recommendation for SLCO1B1 and ABCG2, evidence review underway for CYP2C9, HMGCR, and CYP3A
* *G6PD*/rasburicase update – evidence review complete, starting to draft recommendations, many more drugs will be included
* SSRI update – early stages of evidence review, will include additional genes and drugs (e.g., SNRIs)
* *MT-RNR1*/aminoglycosides guideline – in review
* CYP2D6/beta-blockers-authorship plan approved by steering committee; will schedule first call soon
* CYP2D6/antipsychotics-will begin guideline when SSRI evidence review is complete
 | Kelly will continue to follow-up |
| Term standardization | Term standardization part 2 is underway. Kelly reviewed progress. We have consensus for allele clinical function and phenotype for MT-RNR1. These will be posted publicly. Experts working now on modifier terms such as “likely” and “possible”. Slides attached with minutes | Kelly will continue to update. |